Atrial Fibrillation Complications in COVID-19-Infected Patients

Abstract

Atrial fibrillation (AF) is the most prevalent chronic cardiac arrhythmia and frequently occurs with chronic heart failure (CHF) and make them a significant health and survival burden to elderly patients. The outbreak of the COVID-19 pandemic has made this already difficult clinical picture even more complex. The virus enhances cardiovascular dysfunction with effects which include increased inflammatory reactions, destruction of the endothelial cell lining, and a high probability of blood thrombosis. Despite the growing recognition of these intertwined processes, there remains a notable lack of detailed comparative data examining how complications manifest and evolve in patients suffering from both AF and CHF whether or not they have contracted COVID-19. This retrospective analytical investigation was performed at the Cardiology Department of Andijan State Medical Institute and included 285 patients aged 60–74 years diagnosed with AF and CHF. According to the status of COVID-19, there were 145 patients in the group of the infected, and 140 patients as controls. It was shown that the frequency of thromboembolic events in the infected cohort pulmonary embolism (12% vs. 5%), and ischemic stroke (15% vs. 8) were significantly high. Additionally, infectious complications most evidently bacterial pneumonia had much higher incidence in COVID-19-positive patients. These observations highlight the critical influence that the infection of SARS-CoV-2 has on the clinical course of people with both atrial fibrillation and chronic heart failure. Altogether, the information highlights the importance of personalized anticoagulation interventions, strict attention to hemodynamic monitoring, and attentive care to infection prevention. It is a critical point to have such an integrated approach to reduce adverse events and enhance long-term outcomes in such a vulnerable patient group.